CAMP4 to Present New Preclinical Data from its Urea Cycle Disorders and SYNGAP1-Related Disorders Programs at the 28th American Society of Gene and Cell Therapy Annual Meeting
Interim safety data including patient demographic data from all SAD cohorts of the first-in-human Phase 1 clinical trial of CMP-CPS-001 in healthy volunteers to be presented
CAMBRIDGE, Mass., April 28, 2025 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation ('CAMP4') (Nasdaq: CAMP), a clinical-stage biopharmaceutical company developing a pipeline of regulatory RNA-targeting therapeutics designed to upregulate gene expression with the goal of restoring healthy protein levels to treat a broad range of genetic diseases, today announced three oral presentations at the upcoming 28th Annual Meeting of the American Society of Gene and Cell Therapy, taking place in New Orleans, LA, May 13 – 17, 2025.
Details for the oral presentations are as follows:
Title: Targeting Regulatory RNAs with Antisense Oligonucleotides for the Potential Treatment of Urea Cycle DisordersPresenter: Dan Tardiff, Ph.D.Session title: Oligonucleotide Therapeutics IISession date and time: Friday May 16, 2025, 3:45 PM - 5:40 PM CT
Title: Targeting Regulatory RNAs with Antisense Oligonucleotides for the Potential Treatment of SYNGAP1-Related DisordersPresenter: Dan Tardiff, Ph.D.Session title: Oligonucleotide Therapeutics IISession date and time: May 16, 2025, 3:45 PM - 5:40 PM CT
Title: A First-in-Human Double-Blind, Placebo-Controlled Single and Multiple Ascending Dose Study (SAD, MAD) in Healthy Volunteers to Evaluate the Safety and Tolerability of an Investigational Antisense Oligonucleotide Therapy (CMP-CPS-001) for the Treatment of Urea Cycle Diseases (UCDs): Interim Safety ReadoutPresenter: Yuri Maricich, M.D.Session title: Oligonucleotide Therapeutics IISession date and time: May 16, 2025, 3:45 PM - 5:40 PM CT
The presentations will be made available on the CAMP4 website at https://investors.camp4tx.com/news-events/presentations simultaneously with the session.
About CAMP4 Therapeutics
CAMP4 is developing disease-modifying treatments for a broad range of genetic diseases where amplifying healthy protein may offer therapeutic benefits. Our approach amplifies mRNA by harnessing a fundamental mechanism of how genes are controlled. To amplify mRNA, our therapeutic ASO drug candidates target regulatory RNAs (regRNAs), which act locally on transcription factors and are the master regulators of gene expression. CAMP4's proprietary RAP Platform™ enables the mapping of regRNAs and generation of therapeutic candidates designed to target the regRNAs associated with genes underlying haploinsufficient and recessive partial loss-of-function disorders, of which there are more than 1,200, in which a modest increase in protein expression may have the potential to be clinically meaningful. For more information, visit camp4tx.com.
Forward-Looking Statements
This press release contains forward-looking statements which involve risks, uncertainties and contingencies, many of which are beyond the control of the Company, which may cause actual results, performance, or achievements to differ materially from anticipated results, performance, or achievements. All statements other than statements of historical facts contained in this press release are forward-looking statements. In some cases, you can identify forward-looking statements by terms such as 'may,' 'will,' 'should,' 'expect,' 'plan,' 'anticipate,' 'could,' 'intend,' 'target,' 'project,' 'contemplate,' 'believe,' 'estimate,' 'predict,' 'potential' or 'continue' or the negative of these terms or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements include, but are not limited to, statements concerning CAMP4's plans and expectations regarding its ongoing Phase 1 clinical trial of CMP-CPS-001 and its intention to initiate the expansion into a Phase 1b clinical trial of CMP-CPS-001; the anticipated timing and results of the company's ongoing and future clinical trials, including expectations regarding the timing of reporting data from the CMP-CPS-001 clinical trials; the expected timing for the company's initiation of GLP toxicity studies relating to CAMP4's SYNGAP1 program; the therapeutic potential of CAMP4's product candidates; estimates regarding the size of patient populations; and cash runway guidance. The forward-looking statements in this press release speak only as of the date of this press release and are subject to a number of known and unknown risks, uncertainties and assumptions that could cause the Company's actual results to differ materially from those anticipated in the forward-looking statements, including, but not limited to: the Company's limited operating history, incurrence of substantial losses since the Company's inception and anticipation of incurring substantial and increasing losses for the foreseeable future; the Company's need for substantial additional financing to achieve the Company's goals; the uncertainty of clinical development, which is lengthy and expensive, and characterized by uncertain outcomes, and risks related to additional costs or delays in completing, or failing to complete, the development and commercialization of the Company's current product candidates or any future product candidates; delays or difficulties in the enrollment and dosing of patients in clinical trials; the impact of any significant adverse events or undesirable side effects caused by the Company's product candidates; potential competition, including from large and specialty pharmaceutical and biotechnology companies; the Company's ability to realize the benefits of the Company's current or future collaborations or licensing arrangements and ability to successfully consummate future partnerships; the Company's ability to obtain regulatory approval to commercialize any product candidate in the United States or any other jurisdiction, and the risk that any such approval may be for a more narrow indication than the Company seeks; the Company's dependence on the services of the Company's senior management and other clinical and scientific personnel, and the Company's ability to retain these individuals or recruit additional management or clinical and scientific personnel; the Company's ability to grow the Company's organization, and manage the Company's growth and expansion of the Company's operations; risks related to the manufacturing of the Company's product candidates, which is complex, and the risk that the Company's third-party manufacturers may encounter difficulties in production; the Company's ability to obtain and maintain sufficient intellectual property protection for the Company's product candidates or any future product candidates the Company may develop; the Company's reliance on third parties to conduct the Company's preclinical studies and clinical trials; the Company's compliance with the Company's obligations under the licenses granted to the Company by others, for the rights to develop and commercialize the Company's product candidates; risks related to the operations of the Company's suppliers; and other risks and uncertainties described in the section 'Risk Factors' in the Company's Annual Report on Form 10-K for the year ended December 31, 2024, as well as other information the Company files with the Securities and Exchange Commission. The forward-looking statements in this press release are inherently uncertain and are not guarantees of future events. Because forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified and some of which are beyond the Company's control, you should not unduly rely on these forward-looking statements. The events and circumstances reflected in the forward-looking statements may not be achieved or occur and actual future results, levels of activity, performance and events and circumstances could differ materially from those projected in the forward-looking statements. Moreover, the Company operates in an evolving environment. New risks and uncertainties may emerge from time to time, and management cannot predict all risks and uncertainties. Investors, potential investors, and others should give careful consideration to these risks and uncertainties. Except as required by applicable law, the Company does not undertake to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.
Contacts
Investor Relations:
Dan Ferry (US)LifeSci Advisorsdaniel@lifesciadvisors.com
Sandya von der Weid (Europe)LifeSci Advisorssvonderweid@lifesciadvisors.com
Media:
Jason Braco, Ph.D.LifeSci Communicationsjbraco@lifescicomms.comSign in to access your portfolio
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
32 minutes ago
Asian shares mostly gain as eyes turn to meetings at the White House and Jackson Hole
BANGKOK -- Asian shares were mostly higher Monday after the S&P 500 and Nasdaq composite edged back from their record levels while the Dow inched to a new record close. U.S. futures were little changed as investors watched for developments in the Ukraine crisis following a summit between President Donald Trump and Russian President Vladimir Putin that brought no breakthroughs. Japan's Nikkei 225 gained 0.8% to 43.714.31, while the Hang Seng in Hong Kong added 0.1% to 25,291.42. The Shanghai Composite index jumped 1% to 3,732.44. Australia's S&P/ASX 200 picked up 0.2% to 8,959.30. The Kospi in South Korea declined 1.5% to 3,177.28 on heavy selling of semiconductor makers like Samsung Electronics, whose shares fell 2.2%. SK Hynix lost 3.3% as investors fretted over the possibility of more U.S. tariffs on computer chips. Trump was preparing to meet later Monday with Ukrainian President Volodymyr Zelenskyy and other European leaders in Washington. The European vanguard were not included in Trump's summit with Russian President Vladimir Putin last Friday. They are seeking to present a united front in safeguarding Ukraine and the continent from any widening aggression from Moscow. An annual meeting in Jackson Hole, Wyoming, of top central bankers later this week will be watched closely for hints about possible interest rate cuts from Federal Reserve chair Jerome Powell. He is due to speak Friday at the economic policy conference. 'While the official theme is labor markets, investors will scrutinize any hint of September policy direction, especially after last week's mixed inflation data,' Ipek Ozkardeskaya of Swissquote said in a commentary, adding that 'any progress on Ukraine peace talks could push global equities higher still.' Expectations have been building that the Fed will cut interest rates at its next meeting in September, though mixed reports on the U.S. economy have undercut those bets somewhat. One report Friday said shoppers boosted their spending at U.S. retailers last month, while another said manufacturing in New York state unexpectedly grew. A third said industrial production across the country shrank last month, when economists were looking for modest growth. Yet another report suggested sentiment among U.S. consumers is worsening because of worries about inflation, when economists expected to see a slight improvement. On Wall Street, UnitedHealth Group jumped 12% on Friday after famed investor Warren Buffett's Berkshire Hathaway said it bought nearly 5 million shares of the insurer during the spring, valued at $1.57 billion. Buffett is known for trying to buy good stocks at affordable prices, and UnitedHealth's halved for the year by the end of July because of a run of struggles. Berkshire Hathaway's own stock slipped 0.4%. Applied Materials helped lead Wall Street lower with a decline of 14.1% even though it reported better results for the latest quarter than analysts expected. The focus was on the company's forecast for a drop in revenue during the current quarter. Its products help manufacture semiconductors and advanced displays, and CEO Gary Dickerson pointed to a 'dynamic macroeconomic and policy environment, which is creating increased uncertainty and lower visibility in the near term, including for our China business.' Sandisk fell 4.6% despite reporting a profit for the latest quarter that blew past analysts' expectations. Investors focused instead on the data storage company's forecast for profit in the current quarter, which came up short of Wall Street's. On Friday, the S&P 500 fell 0.3%. The Dow Jones Industrial Average edged 0.1% higher. The Nasdaq composite sank 0.4%. In other dealings early Monday, U.S. benchmark crude oil rose 24 cents to $63.04 per barrel, while Brent crude, the international standard, climbed 16 cents to $66.01 per barrel.
Yahoo
an hour ago
- Yahoo
Asia-Pacific Electric Toothbrush Market Outlook Report to 2030, By Country, Competition, Forecast & Opportunities
The Asia-Pacific electric toothbrush market thrives on opportunities like rising oral health awareness, tech innovations, and increasing disposable incomes. Smart features integrated into toothbrushes appeal to tech-savvy and health-conscious consumers. However, high costs pose adoption challenges in price-sensitive regions. Asia-Pacific Electric Toothbrush Market Dublin, Aug. 18, 2025 (GLOBE NEWSWIRE) -- The "Asia-Pacific Electric Toothbrush Market, By Country, Competition, Forecast & Opportunities, 2020-2030F" has been added to offering. The Asia-Pacific Electric Toothbrush Market was valued at USD 1.48 Billion in 2024, and is expected to reach USD 2.77 Billion by 2030, rising at a CAGR of 11.07%. Technological innovation has been a key driver in the adoption of electric toothbrushes across the region. Features such as multiple brushing modes, pressure sensors, and timers have enhanced the efficacy and user experience of these devices. Additionally, the integration of smart technologies, including app connectivity and real-time feedback, has appealed to tech-savvy consumers, further boosting market growth. Rising disposable incomes, particularly in emerging markets like China and India, have enabled consumers to invest in premium oral care products. As urbanization accelerates and lifestyles become more fast-paced, the demand for efficient and time-saving dental care solutions has increased. Electric toothbrushes, with their superior plaque removal capabilities and user-friendly features, have become a preferred choice among consumers seeking effective oral hygiene solutions. Projections indicate that consumer spending in India will increase to USD 4.3 trillion by 2030, up from USD 2.4 trillion in 2024. This growth is primarily driven by the expanding middle and upper-middle-income population, resulting in greater purchasing power and higher discretionary spending. Market Drivers Rising Awareness of Oral Hygiene and Preventive Dental Care: The growing emphasis on personal health and wellness has significantly increased awareness of oral hygiene across the Asia-Pacific region. Consumers are becoming more educated about the long-term benefits of maintaining proper oral care routines, leading to a shift from traditional manual toothbrushes to more advanced and effective solutions like electric toothbrushes. Dental professionals increasingly recommend electric toothbrushes due to their superior plaque removal and ability to improve gum health, further validating their usage among health-conscious individuals. Governments and health organizations are also playing a crucial role by promoting oral health through educational campaigns and public health initiatives. For instance, awareness programs targeting school children and rural populations have contributed to a broader understanding of the importance of dental hygiene. As a result, the demand for electric toothbrushes is rising not only among urban populations but also in semi-urban and rural areas. Furthermore, the integration of features like pressure sensors, timers, and mobile app connectivity in electric toothbrushes enhances user compliance and optimizes brushing techniques. According to The Global Oral Health Status Report (GOHSR) 2022, India faced significant oral health challenges. It accounted for 18.1% of global cases of caries in permanent teeth, 20.3% of severe periodontal disease, and 18.9% of caries in deciduous teeth. Additionally, 9.9% of worldwide cases of edentulism affected 34,905,533 people in India, and the country represented 23.4% of global lip and oral cavity cancer cases, with 327,648 affected individuals. Key Market Challenges High Cost and Affordability Issues: One of the most significant challenges facing the Asia-Pacific electric toothbrush market is the relatively high cost of electric toothbrushes compared to traditional manual ones. In price-sensitive markets like India, Indonesia, and other Southeast Asian countries, the cost of an electric toothbrush especially premium models with advanced features can be a barrier to mass adoption. While the urban middle and upper classes are increasingly able to afford these products, a large portion of the population still sees them as luxury items rather than everyday essentials. This affordability issue is further compounded by the need for periodic replacement heads, which add to the long-term cost of ownership. In rural or less-developed areas, where income levels are lower and awareness about advanced oral care tools is limited, the adoption rate remains minimal. Even if consumers are aware of the benefits, budget constraints often drive them toward cheaper, manual alternatives. To address this challenge, manufacturers must consider offering more affordable, entry-level electric toothbrushes without compromising essential features. Key Market Trends Growing Adoption of Smart and Connected Toothbrushes: The integration of smart technology into electric toothbrushes is rapidly gaining traction in the Asia-Pacific market. Consumers, particularly tech-savvy individuals and the younger population, are increasingly drawn to toothbrushes that offer Bluetooth connectivity, app synchronization, and real-time brushing feedback. These smart toothbrushes are capable of tracking brushing habits, providing personalized recommendations, and improving technique through interactive mobile apps. Brands are leveraging data analytics and AI to create customized oral care routines based on individual user behavior. Features such as pressure sensors, brushing timers, and zone-based cleaning guides not only enhance efficiency but also encourage users to maintain a consistent oral hygiene regimen. This trend aligns with the broader health-tech movement in the region, where consumers are adopting wearable health devices and smart home healthcare tools. The growing popularity of digital health monitoring, combined with the rise of e-commerce, is fueling demand for connected toothbrushes. As urban consumers in countries like Japan, South Korea, and Singapore look for premium wellness products, smart electric toothbrushes are becoming a lifestyle choice, not just a hygiene product. Key Market Players Colgate-Palmolive Company The Procter & Gamble Company Church & Dwight Co., Inc. Koninklijke Philips N.V. Omron Healthcare, Inc. Panasonic Corporation FOREO Wellness Oral Care Bayer AG Pierre Fabre Report Scope: In this report, the Asia-Pacific Electric Toothbrush Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below: Asia-Pacific Electric Toothbrush Market, By Technology: Vibrational Rotational Asia-Pacific Electric Toothbrush Market, By End User: Children Adult Asia-Pacific Electric Toothbrush Market, By Sales Channel: Supermarkets/Hypermarkets Convenience Stores Pharmacy Stores Online Others Asia-Pacific Electric Toothbrush Market, By Country: China Japan India South Korea Australia Rest of Asia Pacific Key Attributes: Report Attribute Details No. of Pages 133 Forecast Period 2024 - 2030 Estimated Market Value (USD) in 2024 $1.48 Billion Forecasted Market Value (USD) by 2030 $2.77 Billion Compound Annual Growth Rate 11.0% Regions Covered Asia Pacific For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Attachment Asia-Pacific Electric Toothbrush Market CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900
USA Today
an hour ago
- USA Today
Liberals play partisan games with economic news
Will Democrats put politics aside and applaud as the American economy shows a strength and resilience that so many of them doubted? Probably not. Thanks to President Donald Trump's bold policies, it appears that the United States will avoid a recession this year − one that so many liberals were predicting only months ago. Will Democrats put politics aside and applaud as the American economy shows a strength and resilience that so many of them doubted? Probably not. The Bureau of Economic Analysis on July 30 released more good news about our nation's vibrant economy. Gross domestic product grew a healthy annual rate of 3% in the second quarter after recording a less than 1% decline in the first three months of this year. Fears of a recession should now dissipate like morning haze after the sunrise. Nearly all markers of a strong economy are in top form. Unemployment is low, hovering at 4.1%. The past three months have seen steady job growth. Average hourly earnings for U.S. workers grew 3.7% over the 12 months ending in June. Consumer spending is expected to rise, and there's been a modest uptick in consumer confidence. The Consumer Price Index, which measures inflation, increased 2.7% over the 12 months ending in June, far below the 40-year high recorded in President Joe Biden's term. Even the average price of eggs has dropped dramatically, to $3.31 per dozen, down from a spike to $8 in February and back to roughly the same price level as a year ago. Stock indexes continue to grow at a strong pace, recovering from the sell-off this spring driven by concerns over Trump's tariffs. The Nasdaq and S&P 500 have set multiple record highs in July, a boon to millions of Americans with retirement accounts and other investors. On the tariff front, Trump's new trade deal with the European Union should be a catalyst for further economic growth, particularly in the energy and construction sectors. If this is what a recession looks like, let's keep it coming. Critics said Trump was destroying the economy Despite such healthy economic markers, I doubt I'll see many kudos offered to the Trump administration for powering past a recession, which the left predicted in doomsday terms. Nobel Prize-winning economist Paul Krugman wrote in May that Trump and "MAGAnomics" were "destroying the economy and waging war on the middle class and the poor." The headline thundered that Trump was "making America backward again." Opinion: Trump's EU trade deal ushers in a golden age for blue-collar workers Interestingly, Krugman claimed that the U.S. economy was in good overall shape when Biden left office in January. He charged Trump with wrecking the economy in a mere three months. Now, that the data clearly shows otherwise, will Krugman admit his errors? I doubt it. Krugman, to be fair, wasn't the only so-called expert spouting off about our supposedly crumbling economy. CNN published an analysis in April with a headline that claimed "Trump took the US economy to the brink of a crisis in just 100 days." That same month, the Center for American Progress bemoaned that "President Donald Trump's decision to unilaterally launch a global trade war could be one of the worst economic statecraft blunders in American history." Opinion newsletter: Sign up for our newsletter on conservative values, family and religion from columnist Nicole Russell. Get it delivered to your inbox. I read these articles in the mainstream news media and wonder if we share the same universe. Do progressives not see the same healthy economic markers that millions of other Americans and I see? The answer, of course, is that they do see − but they are too blinded by partisanship to admit it. Good economic news should be nonpartisan I don't have a problem with liberals criticizing Trump. Sometimes he deserves it. But when it comes to obvious wins like a blossoming economy, the constant derision is tiresome and pedestrian. A robust economy under any president is good news for Americans, regardless of their party affiliation. Right? I didn't care for Biden's leftist policies. But I didn't cheer when the economy struggled. It was bad news not just for Biden but, far more important, also for our nation and its citizens. More than a year after Biden entered the White House, annual inflation spiked to 9% in June 2022, the highest rate in four decades. Americans were hit with sudden increases in food, housing and transportation costs. Opinion: Nvidia CEO says Trump gives America an advantage. Hear that, progressives? Compounding the pain, the Federal Reserve acted to cool inflation by raising interest rates, which pushed up consumers' payments for auto, housing and credit card loans. Democrats tried to blame decisions made in Trump's first term, including federal spending used to fight consequences of the COVID-19 pandemic. But Biden spent more even as the pandemic began to wane. In 2024, more than half of American voters said the economy was the issue that mattered to them the most. It's why Trump won more than 77 million votes and returned to the White House. Now, he is delivering on his promises to rebuild our nation's economy. But not everyone is happy about it. It's too bad liberals can't separate economic success from Trump's party affiliation. I can't help but wonder if they wanted a recession so they could blame Trump even more. Nicole Russell is a columnist at USA TODAY and a mother of four who lives in Texas. Contact her at nrussell@ and follow her on X, formerly Twitter: @russell_nm. Sign up for her weekly newsletter, The Right Track, here. You can read diverse opinions from our USA TODAY columnists and other writers on the Opinion front page, on X, formerly Twitter, @usatodayopinion and in our Opinion newsletter.
